Company Research Report: ReviveMed Inc.

Company Overview

• Name: ReviveMed Inc.

• Mission: Revolutionizing Precision Medicine with the Power of AI and Metabolites.

• Founded: No information is available.

• Founders:

• Dr. Leila Pirhaji, Co-Founder & CEO, expert in AI and biology.

• Prof. Ernest Fraenkel, Co-Founder & Board Member, Professor of Biological Engineering at MIT.

• Key People:

• Dr. Leila Pirhaji, Co-Founder & CEO.

• Prof. Ernest Fraenkel, Co-Founder & Board Member.

• Dr. Andrey Zarur, Board of Directors, CEO at GreenLight Biosciences.

• Dr. Maria Karasarides, Scientific Advisor, former VP at BMS.

• Prof. Regina Barzilay, Scientific Advisor, Professor of Computer Science at MIT.

• Dr. Clary Clish, Scientific Advisor, Director of Metabolomics at the Broad Institute of MIT & Harvard.

• Prof. Matthew Vander Heiden, Scientific Advisor, Professor of Biology at MIT.

• Dr. Nazli Azimi, Executive Advisor, Biotech Executive.

• Natanel Barookhian, Board of Directors.

• Carlos Gonzales, Board of Directors, Founder of Rivas Capital.

• Dr. Rui Zhang, Business Advisor.

• Headquarters: 245 First St., Cambridge, MA, 02142.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Utilizing AI and metabolomics to create precision medicine solutions, known for its innovative approach to analyze metabolites for health and disease management.

Products

Overview

ReviveMed offers a range of advanced AI and metabolomics-based healthcare solutions. Their product offerings focus on leveraging large datasets of metabolites to create accurate predictive health models.

Precision Obesity

• Description: An AI-driven tool that creates digital metabolic twins to predict metabolic health beyond traditional measures like BMI.

• Key Features:

• Uses over 10,000 lipids and metabolites.

• Provides insights into metabolic health risks including Type 2 Diabetes (T2D), Cardiovascular Disease (CVD), etc.

Precision Oncology

• RCC Metabolic Twins

• Description: AI models simulating renal cell carcinoma patients to predict treatment responses.

• Key Features: Accurate prediction for patient responses to cancer immunotherapy.

• Immuno-Oncology

• Description: Solutions to optimize cancer immunotherapy responses.

• Key Features:

• Predicts potential beneficiaries of immunotherapy.

• Addresses issues of non-responses and adverse effects.

• "The Obesity Paradox"

• Description: An analysis framework revealing why obese patients may have better immunotherapy responses.

• Key Features: Detects changes in blood metabolites to study systematic metabolic changes in cancer.

Recent Developments

• New Products/Features: The company has advanced in developing virtual patients and metabolic twins which simulate health, disease, and treatment responses.

• Partnerships:

• Engaging with multi-modal metabolomics data to expand patient treatment indications.

• Collaborating with Bristol Myers Squibb for AI-driven metabolomics studies.

• Presentations and Recognitions:

• Presented research at ASCO 2024 and SITC 2024.

• Received the Frost & Sullivan AI-Driven Next-Generation Metabolomics Technology Innovation Award.

• ReviveMed CEO Dr. Pirhaji selected as a 35 under 35 innovators by MIT Technology Review.

• Awards:

• Received the Novartis & LabCentral Golden Ticket Award.

This structured report provides an in-depth view of ReviveMed Inc., highlighting its approach to precision medicine through groundbreaking technology integrations.